Health Condition 1: L400- Psoriasis vulgaris
Conditions
Interventions
Intervention1: nil: Nil
Intervention2: Nil: Nil
Intervention3: Nil: Nil
Intervention4: Nil: Nil
Sponsors
Department of Health Research under MoHFW
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with confirmed diagnosis of moderate to severe plaque psoriasis by a dermatologist, requiring cyclosporine for management as adjudicated by dermatologist 2. Patients with completed age between 18-65 years (both inclusive) of either gender 3. Patients willing to stay adherent to treatment
Exclusion criteria
Exclusion criteria: 1. Patients with pustular, erythrodermic, and/or guttate forms of psoriasis (non-plaque forms of psoriasis) 2. Any reason as per the judgement of the dermatologist which may cause any harm to the patient by cyclosporine treatment 3. Patient not willing to give written informed consent 4. Patients which are half medicated. 5. patients who had previously taken cyclosporine
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the change in DLQI Scores and EQ5D5L Score in patients of moderate to severe plaque psoriasis from baseline to 12 weeksTimepoint: 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)To evaluate the Safety of cyclosporine in patients of moderate to severe plaque psoriasis from baseline to 12 weeks on the basis of lab reports , blood pressure and by recording and evaluating the severity of adverse events by using modified Hartwig and Siegel scale 2) To evaluate the change in EQ5D5L Scale in patients of moderate to severe plaque psoriasis from baseline to 12 weeks Timepoint: 12 weeks | — |
Countries
India
Contacts
Public ContactMrunali Sanjay Dudhe
Government Medical College, Nagpur
Outcome results
None listed